Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 15/20 | 0.80 |
| ▸ | ACACA | Q13085 | 7/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29675650 | 0.96 | ACACB (0.86) | ACACBACACAPLK1KDM4EHTT | |
| SCHEMBL256438 | 0.89 | ACACB (1.00) | ACACBPLK1 | |
| SCHEMBL12001190 | 0.83 | ACACB (0.68) | ACACBSMN1; SMN2GAAMAPT | |
| SCHEMBL12001062 | 0.81 | ACACB (0.81) | ACACBACACAPLK1KDM4EHTT | |
| SCHEMBL255804 | 0.81 | ACACB (0.81) | ACACBACACAPLK1ALDH1A1GAA | |
| SCHEMBL469916 | 0.78 | ACACB (0.50) | ACACBACACAPLK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL256437 | 0.77 | ACACB (1.00) | ACACB | |
| SCHEMBL15577932 | 0.76 | ACACB (0.49) | ACACBKDM4EHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL27254652 | 0.76 | ACACB (0.54) | ACACBSMN1; SMN2GAAMAPT | |
| SCHEMBL15578173 | 0.75 | KDM4E (0.52) | ACACBKDM4EHTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214785-A1 | New compounds, pharmaceutical compositions and uses thereof | ABCG2, PGA5, PDE6G | ACACB 2257/4885ACACA 1796/4885PLK1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.